Celcuity (CELC) Tops Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Celcuity Reports First Quarter 2019 Financial Results
May 7, 2019 4:01 PM EDTMINNEAPOLIS--(BUSINESS WIRE)-- Celcuity Inc. (Nasdaq: CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the first quarter ended March 31, 2019.
Unless otherwise stated, all comparisons are for the first quarter ended March 31, 2019, compared to the first quarter ended March 31, 2018.
Celcuity reported a net loss of $1.85 million, or $0.18 per share, for the first quarter of 2019, compared to a net loss of $1.97 million, or $0.19 per share, for the first quarter of... More
